Symbols / XAIR $0.80 -3.60%
XAIR Chart
About
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 8.42M |
| Enterprise Value | 20.84M | Income | -31.00M | Sales | 6.92M |
| Book/sh | 0.96 | Cash/sh | 1.11 | Dividend Yield | — |
| Payout | 0.00% | Employees | 61 | IPO | — |
| P/E | — | Forward P/E | -0.48 | PEG | — |
| P/S | 1.22 | P/B | 0.83 | P/C | — |
| EV/EBITDA | -0.81 | EV/Sales | 3.01 | Quick Ratio | 2.59 |
| Current Ratio | 5.12 | Debt/Eq | 284.71 | LT Debt/Eq | — |
| EPS (ttm) | -4.47 | EPS next Y | -1.66 | EPS Growth | — |
| Revenue Growth | 104.70% | Earnings | 2026-02-13 | ROA | -51.20% |
| ROE | -240.21% | ROIC | — | Gross Margin | 1.82% |
| Oper. Margin | -3.01% | Profit Margin | 0.00% | Shs Outstand | 10.53M |
| Shs Float | 9.41M | Short Float | 1.53% | Short Ratio | 0.50 |
| Short Interest | — | 52W High | 6.40 | 52W Low | 0.67 |
| Beta | 0.42 | Avg Volume | 7.77M | Volume | 108.07K |
| Target Price | $8.67 | Recom | Buy | Prev Close | $0.83 |
| Price | $0.80 | Change | -3.60% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$8.67
Mean price target
2. Current target
$0.80
Latest analyst target
3. DCF / Fair value
$-31.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.80
Low
$2.00
High
$14.00
Mean
$8.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-10 | main | D. Boral Capital | Buy → Buy | $10 |
| 2026-01-21 | main | D. Boral Capital | Buy → Buy | $11 |
| 2025-11-11 | main | D. Boral Capital | Buy → Buy | $11 |
| 2025-08-21 | main | D. Boral Capital | Buy → Buy | $11 |
| 2025-08-13 | main | D. Boral Capital | Buy → Buy | $11 |
| 2025-07-17 | init | D. Boral Capital | — → Buy | $11 |
| 2024-08-07 | main | Piper Sandler | Overweight → Overweight | $1 |
| 2024-06-25 | main | Piper Sandler | Overweight → Overweight | $4 |
| 2024-06-25 | down | BTIG | Buy → Neutral | — |
| 2024-04-30 | main | Truist Securities | Buy → Buy | $8 |
| 2023-11-14 | main | Truist Securities | Buy → Buy | $10 |
| 2023-07-28 | init | Piper Sandler | — → Overweight | $10 |
| 2023-07-21 | main | Truist Securities | Buy → Buy | $14 |
| 2023-06-23 | main | Oppenheimer | Outperform → Outperform | $10 |
| 2023-06-15 | init | BTIG | — → Buy | $15 |
| 2022-06-29 | main | Truist Securities | — → Buy | $20 |
| 2022-06-29 | main | Ladenburg Thalmann | — → Buy | $23 |
| 2021-11-12 | main | Truist Securities | — → Buy | $16 |
| 2021-04-28 | init | Truist Securities | — → Buy | $12 |
| 2019-10-22 | init | Oppenheimer | — → Outperform | $9 |
- Beyond Air drops NeuroNOS sale, rethinks neurological and cancer plans - Stock Titan ue, 10 Mar 2026 11
- XAIR Stock Price, Quote & Chart | BEYOND AIR INC (NASDAQ:XAIR) - ChartMill ue, 10 Mar 2026 07
- How The Narrative On Beyond Air (XAIR) Is Resetting Around LungFit PH And Delayed Approval - Yahoo Finance Wed, 25 Feb 2026 08
- Beyond Air Stock (XAIR) Opinions on NeuroNOS Acquisition Deal | XAIR Stock News - Quiver Quantitative ue, 13 Jan 2026 08
- XAIR Stock More Than Doubled Today — What’s Driving The Rally? - Stocktwits ue, 13 Jan 2026 08
- XAIR stock Beyond Air (NASDAQ) $2.22 intraday 13 Jan 2026: XTL deal lifts volume - Meyka ue, 13 Jan 2026 08
- Beyond Air (XAIR) Buy Rating Reaffirmed by D. Boral Capital | XA - GuruFocus ue, 10 Mar 2026 17
- Why Is Beyond Air Stock (XAIR) Up Today? - TipRanks ue, 13 Jan 2026 08
- With Beyond Air Stock Sliding, Have You Assessed The Risk? - Trefis Mon, 22 Dec 2025 08
- Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR) - The Globe and Mail hu, 12 Mar 2026 19
- Beyond Air (XAIR) stock whipsaws after NeuroNOS deal — premarket drop follows 150% rally - TechStock² Wed, 14 Jan 2026 08
- Beyond Air raises $5M in stock-and-warrant sale to institutional buyer - Stock Titan Wed, 14 Jan 2026 08
- $XAIR stock is down 18% today. Here's what we see in our data. - Quiver Quantitative Wed, 22 Oct 2025 07
- Beyond Air Inc (XAIR) Expands Focus on Nitric Oxide Therapies - Yahoo Finance Wed, 04 Mar 2026 08
- Two Nobel laureates back new autism drug effort in XTL’s NeuroNOS deal - Stock Titan ue, 13 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 6000 | 19491 | — | Purchase at price 3.25 per share. | LISI STEVEN A | Chief Executive Officer | — | 2025-07-21 00:00:00 | D |
| 1 | 1000000 | 250050 | — | Purchase at price 0.25 - 0.26 per share. | CAREY ROBERT F. | Director | — | 2025-03-14 00:00:00 | D |
| 2 | 6000 | 2294 | — | Purchase at price 0.38 per share. | GAUL MICHAEL A | Chief Operating Officer | — | 2025-02-19 00:00:00 | D |
| 3 | 1476626 | 744662 | — | Purchase at price 0.50 per share. | CAREY ROBERT F. | Director | — | 2024-09-26 00:00:00 | I |
| 4 | 1476626 | 744662 | — | Purchase at price 0.50 per share. | LISI STEVEN A | Chief Executive Officer | — | 2024-09-26 00:00:00 | D |
| 5 | 50000 | 18340 | — | Purchase at price 0.37 per share. | LISI STEVEN A | Chief Executive Officer | — | 2024-08-15 00:00:00 | D |
| 6 | 100000 | 39680 | — | Purchase at price 0.40 per share. | CAREY ROBERT F. | Director | — | 2024-08-14 00:00:00 | D |
| 7 | 39266 | 15565 | — | Purchase at price 0.40 per share. | LUCERA ERICK J. | Director | — | 2024-08-14 00:00:00 | D |
| 8 | 100000 | 38640 | — | Purchase at price 0.39 per share. | LISI STEVEN A | Chief Executive Officer | — | 2024-08-14 00:00:00 | D |
| 9 | 602410 | 1000001 | — | Stock Award(Grant) at price 1.66 per share. | CAREY ROBERT F. | Director | — | 2024-03-20 00:00:00 | D |
Financials
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -40.96M | -61.42M | -58.75M | -32.06M |
| TotalUnusualItems | -932.00K | 2.39M | 551.00K | -10.64M |
| TotalUnusualItemsExcludingGoodwill | -932.00K | 2.39M | 551.00K | -10.64M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -46.62M | -60.24M | -55.82M | -43.18M |
| ReconciledDepreciation | 3.57M | 2.35M | 1.17M | 588.00K |
| ReconciledCostOfRevenue | 5.37M | 2.47M | 555.00K | 0.00 |
| EBITDA | -41.89M | -59.03M | -58.20M | -42.70M |
| EBIT | -45.46M | -61.38M | -59.37M | -43.28M |
| NetInterestIncome | -3.02M | -2.91M | -30.00K | -775.00K |
| InterestExpense | 3.02M | 2.91M | 30.00K | 775.00K |
| NormalizedIncome | -45.69M | -62.63M | -56.37M | -32.54M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -46.62M | -60.24M | -55.82M | -43.18M |
| TotalExpenses | 48.24M | 64.17M | 52.06M | 30.21M |
| TotalOperatingIncomeAsReported | -44.54M | -63.01M | -52.06M | -40.71M |
| DilutedAverageShares | 3.39M | 1.66M | 1.50M | 1.28M |
| BasicAverageShares | 3.39M | 1.66M | 1.50M | 1.28M |
| DilutedEPS | -13.80 | -36.40 | -37.20 | -33.60 |
| BasicEPS | -13.80 | -36.40 | -37.20 | -33.60 |
| DilutedNIAvailtoComStockholders | -46.62M | -60.24M | -55.82M | -43.18M |
| NetIncomeCommonStockholders | -46.62M | -60.24M | -55.82M | -43.18M |
| NetIncome | -46.62M | -60.24M | -55.82M | -43.18M |
| MinorityInterests | 1.85M | 4.05M | 3.58M | 882.00K |
| NetIncomeIncludingNoncontrollingInterests | -48.48M | -64.30M | -59.40M | -44.06M |
| NetIncomeContinuousOperations | -48.48M | -64.30M | -59.40M | -44.06M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -48.48M | -64.30M | -59.40M | -44.06M |
| OtherIncomeExpense | -923.00K | 1.62M | -7.31M | -13.07M |
| OtherNonOperatingIncomeExpenses | 9.00K | -767.00K | -7.86M | -2.44M |
| SpecialIncomeCharges | -3.19M | 0.00 | 0.00 | -10.50M |
| GainOnSaleOfPPE | -738.00K | 0.00 | ||
| OtherSpecialCharges | 2.45M | 598.00K | 7.86M | 10.50M |
| GainOnSaleOfSecurity | 2.25M | 2.39M | 551.00K | -140.00K |
| NetNonOperatingInterestIncomeExpense | -3.02M | -2.91M | -30.00K | -775.00K |
| InterestExpenseNonOperating | 3.02M | 2.91M | 30.00K | 775.00K |
| OperatingIncome | -44.54M | -63.01M | -52.06M | -30.21M |
| OperatingExpense | 42.87M | 61.70M | 51.50M | 30.21M |
| ResearchAndDevelopment | 16.86M | 24.36M | 16.81M | 11.80M |
| SellingGeneralAndAdministration | 26.02M | 37.34M | 34.69M | 18.41M |
| GeneralAndAdministrativeExpense | 26.02M | 37.34M | 34.69M | 18.41M |
| OtherGandA | 26.02M | 37.34M | 34.69M | 18.41M |
| GrossProfit | -1.66M | -1.31M | -555.00K | 0.00 |
| CostOfRevenue | 5.37M | 2.47M | 555.00K | 0.00 |
| TotalRevenue | 3.71M | 1.16M | 0.00 | 0.00 |
| OperatingRevenue | 3.71M | 1.16M | 0.00 | 0.00 |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 4.13M | 2.30M | 1.54M | 1.49M |
| ShareIssued | 4.13M | 2.30M | 1.54M | 1.49M |
| NetDebt | 5.14M | 4.14M | ||
| TotalDebt | 11.69M | 17.84M | 3.59M | 3.49M |
| TangibleBookValue | 12.36M | 23.62M | 36.28M | 70.87M |
| InvestedCapital | 23.39M | 40.57M | 38.81M | 73.83M |
| WorkingCapital | 11.02M | 32.37M | 39.63M | 82.23M |
| NetTangibleAssets | 12.36M | 23.62M | 36.28M | 70.87M |
| CapitalLeaseObligations | 1.88M | 2.32M | 2.70M | 2.36M |
| CommonStockEquity | 13.58M | 25.05M | 37.91M | 72.70M |
| TotalCapitalization | 22.78M | 39.77M | 38.03M | 72.90M |
| TotalEquityGrossMinorityInterest | 14.34M | 27.19M | 42.03M | 78.21M |
| MinorityInterest | 758.00K | 2.14M | 4.11M | 5.50M |
| StockholdersEquity | 13.58M | 25.05M | 37.91M | 72.70M |
| GainsLossesNotAffectingRetainedEarnings | -60.00K | -15.00K | 53.00K | 96.00K |
| OtherEquityAdjustments | -60.00K | -15.00K | 53.00K | 96.00K |
| TreasuryStock | 25.00K | 25.00K | 25.00K | 25.00K |
| RetainedEarnings | -286.32M | -239.70M | -179.46M | -123.64M |
| AdditionalPaidInCapital | 299.98M | 264.78M | 217.34M | 196.27M |
| CapitalStock | 8.00K | 5.00K | 3.00K | 3.00K |
| CommonStock | 8.00K | 5.00K | 3.00K | 3.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 15.72M | 29.77M | 26.72M | 20.99M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 10.72M | 18.21M | 6.94M | 10.28M |
| OtherNonCurrentLiabilities | 4.50M | 8.00M | 1.00K | |
| DerivativeProductLiabilities | 38.00K | 1.59M | 0.00 | |
| NonCurrentAccruedExpenses | 4.50M | 8.00M | 0.00 | |
| TradeandOtherPayablesNonCurrent | 8.00M | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 10.68M | 16.62M | 2.44M | 2.28M |
| LongTermCapitalLeaseObligation | 1.49M | 1.90M | 2.32M | 2.08M |
| LongTermDebt | 9.20M | 14.72M | 120.00K | 200.00K |
| CurrentLiabilities | 5.00M | 11.57M | 19.78M | 10.71M |
| OtherCurrentLiabilities | 223.00K | 274.00K | 183.00K | 83.00K |
| CurrentDeferredLiabilities | 0.00 | 138.00K | 0.00 | 0.00 |
| CurrentDeferredRevenue | 0.00 | 138.00K | 0.00 | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 1.00M | 1.22M | 1.15M | 1.21M |
| CurrentCapitalLeaseObligation | 396.00K | 418.00K | 376.00K | 281.00K |
| CurrentDebt | 609.00K | 800.00K | 775.00K | 927.00K |
| OtherCurrentBorrowings | 609.00K | 800.00K | 775.00K | 927.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 985.00K | 409.00K | 270.00K | |
| PayablesAndAccruedExpenses | 3.77M | 9.94M | 18.45M | 9.42M |
| CurrentAccruedExpenses | 1.82M | 7.99M | 16.43M | 8.29M |
| Payables | 1.95M | 1.95M | 2.02M | 1.13M |
| OtherPayable | 4.00M | |||
| AccountsPayable | 1.95M | 1.95M | 2.02M | 1.13M |
| TotalAssets | 30.06M | 56.96M | 68.75M | 99.20M |
| TotalNonCurrentAssets | 14.04M | 13.03M | 9.34M | 6.25M |
| OtherNonCurrentAssets | 103.00K | 113.00K | 212.00K | 207.00K |
| GoodwillAndOtherIntangibleAssets | 1.22M | 1.43M | 1.63M | 1.84M |
| OtherIntangibleAssets | 1.22M | 1.43M | 1.63M | 1.84M |
| NetPPE | 12.72M | 11.48M | 7.50M | 4.21M |
| AccumulatedDepreciation | -5.50M | -3.02M | -1.25M | -767.00K |
| GrossPPE | 18.22M | 14.51M | 8.75M | 4.98M |
| Leases | 521.00K | 612.00K | 581.00K | 404.00K |
| OtherProperties | 16.27M | 12.50M | 6.88M | 3.90M |
| MachineryFurnitureEquipment | 1.43M | 1.39M | 1.28M | 675.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 16.02M | 43.94M | 59.41M | 92.94M |
| OtherCurrentAssets | 203.00K | 277.00K | 338.00K | 508.00K |
| RestrictedCash | 231.00K | 230.00K | 7.61M | 9.99M |
| PrepaidAssets | 5.39M | 6.29M | 3.80M | 1.25M |
| Inventory | 2.42M | 2.13M | 1.13M | 350.00K |
| OtherInventories | 350.00K | |||
| Receivables | 860.00K | 548.00K | 651.00K | 604.00K |
| OtherReceivables | 420.00K | 322.00K | 425.00K | |
| TaxesReceivable | 150.00K | 229.00K | 231.00K | 282.00K |
| AccountsReceivable | 710.00K | 319.00K | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 6.92M | 34.47M | 45.88M | 80.24M |
| OtherShortTermInvestments | 2.25M | 23.09M | 16.72M | 0.00 |
| CashAndCashEquivalents | 4.67M | 11.38M | 29.16M | 80.24M |
| Line Item | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|
| FreeCashFlow | -44.10M | -61.76M | -36.89M | -24.58M |
| RepaymentOfDebt | -18.05M | -835.00K | -1.01M | -658.00K |
| IssuanceOfDebt | 11.32M | 15.82M | 0.00 | 1.03M |
| IssuanceOfCapitalStock | 23.01M | 27.97M | 3.71M | 72.83M |
| CapitalExpenditure | -5.88M | -5.75M | -3.88M | -1.45M |
| InterestPaidSupplementalData | 1.20M | 1.76M | 36.00K | 340.00K |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 4.90M | 11.61M | 36.77M | 90.23M |
| BeginningCashPosition | 11.61M | 36.77M | 87.71M | 35.27M |
| EffectOfExchangeRateChanges | -45.00K | -77.00K | -43.00K | 96.00K |
| ChangesInCash | -6.67M | -25.08M | -50.90M | 54.87M |
| FinancingCashFlow | 16.65M | 43.17M | 2.70M | 79.45M |
| CashFlowFromContinuingFinancingActivities | 16.65M | 43.17M | 2.70M | 79.45M |
| NetOtherFinancingCharges | 35.00K | |||
| ProceedsFromStockOptionExercised | 365.00K | 217.00K | 0.00 | 6.22M |
| NetCommonStockIssuance | 23.01M | 27.97M | 3.71M | 72.83M |
| CommonStockIssuance | 23.01M | 27.97M | 3.71M | 72.83M |
| NetIssuancePaymentsOfDebt | -6.73M | 14.98M | -1.01M | 371.00K |
| NetShortTermDebtIssuance | -1.01M | 1.03M | 625.00K | |
| ShortTermDebtPayments | -1.01M | -658.00K | -404.09K | |
| ShortTermDebtIssuance | 0.00 | 1.03M | 625.00K | |
| NetLongTermDebtIssuance | -6.73M | 14.98M | -1.01M | 371.00K |
| LongTermDebtPayments | -18.05M | -835.00K | -1.01M | -658.00K |
| LongTermDebtIssuance | 11.32M | 15.82M | 0.00 | 1.03M |
| InvestingCashFlow | 14.90M | -12.23M | -20.59M | -1.45M |
| CashFlowFromContinuingInvestingActivities | 14.90M | -12.23M | -20.59M | -1.45M |
| NetOtherInvestingChanges | 10.00K | 1.00K | -1.00K | |
| NetInvestmentPurchaseAndSale | 20.78M | -6.49M | -16.71M | 0.00 |
| SaleOfInvestment | 51.66M | 122.28M | 18.95M | 0.00 |
| PurchaseOfInvestment | -30.88M | -128.77M | -35.66M | 0.00 |
| NetPPEPurchaseAndSale | -5.88M | -5.75M | -3.88M | -1.45M |
| SaleOfPPE | 1.00K | |||
| PurchaseOfPPE | -5.88M | -5.75M | -3.88M | -1.45M |
| OperatingCashFlow | -38.22M | -56.01M | -33.01M | -23.13M |
| CashFlowFromContinuingOperatingActivities | -38.22M | -56.02M | -33.01M | -23.14M |
| ChangeInWorkingCapital | -6.15M | -16.04M | 5.39M | 11.83M |
| ChangeInOtherWorkingCapital | -873.19K | |||
| ChangeInOtherCurrentLiabilities | -385.00K | -381.00K | -275.00K | 0.00 |
| ChangeInOtherCurrentAssets | 1.05M | -1.58M | 918.00K | -816.00K |
| ChangeInPayablesAndAccruedExpense | -5.96M | -13.18M | 5.63M | 12.55M |
| ChangeInAccruedExpense | -6.36M | -12.71M | 4.79M | 12.87M |
| ChangeInPayable | 399.00K | -467.00K | 838.00K | -327.00K |
| ChangeInAccountPayable | 399.00K | -467.00K | 838.00K | -327.00K |
| ChangeInInventory | -466.00K | -998.00K | -781.00K | 0.00 |
| ChangeInReceivables | -390.00K | 101.00K | -98.00K | 103.00K |
| ChangesInAccountReceivables | -390.00K | -319.00K | 0.00 | |
| OtherNonCashItems | 1.72M | 1.15M | -1.00K | 529.00K |
| StockBasedCompensation | 9.15M | 21.34M | 19.56M | 7.83M |
| UnrealizedGainLossOnInvestmentSecurities | 60.00K | 123.00K | -12.00K | 0.00 |
| ProvisionandWriteOffofAssets | 177.00K | 0.00 | 49.00K | 0.00 |
| AssetImpairmentCharge | 505.00K | 0.00 | ||
| DepreciationAmortizationDepletion | 3.57M | 2.35M | 1.17M | 588.00K |
| DepreciationAndAmortization | 3.57M | 2.35M | 1.17M | 588.00K |
| AmortizationCashFlow | 205.00K | 205.00K | 205.00K | 38.00K |
| AmortizationOfIntangibles | 205.00K | 205.00K | 205.00K | 38.00K |
| Depreciation | 3.37M | 2.15M | 965.00K | 550.00K |
| OperatingGainsLosses | 1.23M | -644.00K | 235.00K | 144.00K |
| GainLossOnInvestmentSecurities | -1.55M | -659.00K | ||
| NetForeignCurrencyExchangeGainLoss | 0.00 | 144.00K | 37.00K | |
| GainLossOnSaleOfPPE | 334.00K | 15.00K | 235.00K | 0.00 |
| NetIncomeFromContinuingOperations | -48.48M | -64.30M | -59.40M | -44.06M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for XAIR
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|